Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alzheimer disease in 2020.

Literature DB >> 23125202

Alzheimer disease in 2020.

David M Holtzman¹, Eckhard Mandelkow, Dennis J Selkoe.

Abstract

Remarkable advances in unraveling the biological underpinnings of Alzheimer disease (AD) have occurred during the last 25 years. Despite this, we have made only the smallest of dents in the development of truly disease-modifying treatments. What will change over the next 10 years? While the answer is not clear, we make several predictions on the state of the field in 2020, based on the rich knowledge described in the other contributions in this collection. As such, our predictions represent some of the principal unresolved questions that we believe deserve special investigative attention in the coming decade.

Entities: Disease

Mesh：

Substances：

Year: 2012 PMID： 23125202 PMCID： PMC3543098 DOI： 10.1101/cshperspect.a011585

Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN： 2157-1422 Impact factor: 6.915

3 in total

Review 1. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Authors: Paul S Aisen; Jeffrey Cummings; Lon S Schneider
Journal: Cold Spring Harb Perspect Med Date: 2012-03 Impact factor: 6.915

Review 2. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

Authors: Virginia M-Y Lee; Kurt R Brunden; Michael Hutton; John Q Trojanowski
Journal: Cold Spring Harb Perspect Med Date: 2011-09 Impact factor: 6.915

Review 3. Treatment strategies targeting amyloid β-protein.

Authors: Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Journal: Cold Spring Harb Perspect Med Date: 2012-09-01 Impact factor: 6.915

3 in total

56 in total

Review 1. Deciphering Alzheimer disease.

Authors: Dennis Selkoe; Eckhard Mandelkow; David Holtzman
Journal: Cold Spring Harb Perspect Med Date: 2012-01 Impact factor: 6.915

2. Caspase-dependent degradation of MDMx/MDM4 cell cycle regulatory protein in amyloid β-induced neuronal damage.

Authors: Daniel J Colacurcio; Jacob W Zyskind; Kelly L Jordan-Sciutto; Cagla Akay Espinoza
Journal: Neurosci Lett Date: 2015-10-22 Impact factor: 3.046

Review 3. Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease.

Authors: Wei Xu; Fang Fang; Jianqing Ding; Chengbiao Wu
Journal: Traffic Date: 2018-02-05 Impact factor: 6.215

Review 4. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.

Authors: Wei Qiao Qiu
Journal: Neuroscience Date: 2017-05-19 Impact factor: 3.590

5. The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor.

Authors: Susan E Kiefer; Chiehying J Chang; S Roy Kimura; Mian Gao; Dianlin Xie; Yaqun Zhang; Guifen Zhang; Martin B Gill; Harold Mastalerz; Lorin A Thompson; Angela M Cacace; Steven Sheriff
Journal: Acta Crystallogr F Struct Biol Commun Date: 2014-01-21 Impact factor: 1.056

6. Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Authors: Shan Liu; Ariel Breitbart; Yanjie Sun; Pankaj D Mehta; Allal Boutajangout; Henrieta Scholtzova; Thomas Wisniewski
Journal: J Neurochem Date: 2013-11-06 Impact factor: 5.372

7. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease.

Authors: Xueli Zhang; Yanli Tian; Zeng Li; Xiaoyu Tian; Hongbin Sun; Hong Liu; Anna Moore; Chongzhao Ran
Journal: J Am Chem Soc Date: 2013-10-25 Impact factor: 15.419

Review 8. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors: David A Bennett; Lei Yu; Philip L De Jager
Journal: Biochem Pharmacol Date: 2014-02-06 Impact factor: 5.858

Review 9. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

Authors: David Hsu; Gad A Marshall
Journal: Curr Alzheimer Res Date: 2017 Impact factor: 3.498

Review 10. Developing therapeutic vaccines against Alzheimer's disease.

Authors: Thomas Wisniewski; Eleanor Drummond
Journal: Expert Rev Vaccines Date: 2015-12-11 Impact factor: 5.217